| |
 | | | | | Lundbeck Continues Strong Growth in Third Quarter [Source: Lundbeck ] |
| |
 | |  |
 [03-Nov-2010] Danish-based H. Lundbeck A/S, a pharmaceutical company specialized in central nervous system (CNS) disorders, reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009. Profit from operations (EBIT) was DKK 846 million, an increase of 8% compared to the same period last year. The EBIT margin for the quarter was 23.4%. Continued strong growth in key products Cipralex®, Ebixa® and Azilect®, growing 11%, 9% and 28%... | | | | | |
|